Journal article
Conversion from intravenous to oral mexiletine in the acute management of repetitive ventricular arrhythmia
Clinical pharmacology and therapeutics, v 37(6), pp 644-648
Jun 1985
PMID: 2408808
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
We evaluated the safety and efficacy of intravenous mexiletine and a method for converting from intravenous to oral mexiletine therapy. Fifteen patients with repetitive ventricular ectopy (13 had ventricular tachycardia) received intravenous mexiletine at a rate of 10 mg/min for 30 to 60 minutes. Ventricular ectopy was suppressed with minimal side effects in 10 of 15 subjects. Oral mexiletine was begun immediately after completion of the intravenous infusion at a dose of 10 mg/kg/24 hr in the 10 responders to intravenous therapy. In eight, the oral dose was effective in suppressing the arrhythmia, but it induced side effects in three of them. In one of these three, dose reduction resulted in adequate arrhythmia control with acceptable toxicity. In the two who did not respond to the original dose, a larger dose (15 mg/kg/24 hr) induced arrhythmia control with acceptable side effects in one subject. Thus rapid control of nonsustained repetitive ventricular arrhythmia can be achieved with intravenous mexiletine in about two thirds of patients, and conversion to oral therapy can often be achieved smoothly without significant arrhythmia recurrence.
Clinical Pharmacology and Therapeutics (1985) 37, 644–648; doi:10.1038/clpt.1985.104
Metrics
Details
- Title
- Conversion from intravenous to oral mexiletine in the acute management of repetitive ventricular arrhythmia
- Creators
- Leonard N Horowitz - Hahnemann University HospitalAllan M Greenspan - Hahnemann University HospitalScott R Spielman - Hahnemann University HospitalSusan J Frye - Hahnemann University HospitalLinda A Yacone - Hahnemann University HospitalDavid T Lowenthal - Hahnemann University Hospital
- Publication Details
- Clinical pharmacology and therapeutics, v 37(6), pp 644-648
- Publisher
- Springer Nature
- Number of pages
- 5
- Grant note
- Boehringer‐lngelheim, Ltd.
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:A1985ALA5100010
- Scopus ID
- 2-s2.0-0021803750
- Other Identifier
- 991019339701304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Pharmacology & Pharmacy